Omega-3 polyunsaturated fatty acids for the treatment of IgA nephropathy

Research output: Contribution to journalReview articlepeer-review

13 Citations (Scopus)


IgA nephropathy is a common disease that causes end-stage renal failure and requires renal replacement therapy. The main purpose of therapeutic intervention in this disease is not limited to improvement of prognosis and prevention of transition to end-stage renal failure, but also prevention of the occurrence of cardiovascular lesions, which increases risk in patients with chronic kidney disease. Steroids and immunosuppressants have been widely used as remission induction therapies; however, the balance between their therapeutic benefits and detrimental side-effects are controversial. In this regard, it is critical to identify alternative therapies which would provide holistic life-long benefits. Currently, the potential of ω-3 fatty acids as anti-inflammatory and inflammation-convergent drugs—especially the remarkable progress of the multifunctional ω-3 polyunsaturated fatty acids (PUFAs)—has garnered attention. In this section, we outline the background and current status of ω-3 PUFA-based treatment in IgA nephropathy.

Original languageEnglish
Article number70
JournalJournal of Clinical Medicine
Issue number7
Publication statusPublished - 2017 Jul 19


  • Aspirin
  • DHA
  • EPA
  • IgA nephropathy
  • ω-3 PUFAs

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Omega-3 polyunsaturated fatty acids for the treatment of IgA nephropathy'. Together they form a unique fingerprint.

Cite this